Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Nuvectis Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NVCT
Nasdaq
8731
https://nuvectis.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Nuvectis Pharma Inc
Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
- Apr 17th, 2024 10:53 am
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
- Apr 8th, 2024 12:30 pm
5 Healthcare Stocks to Buy for 2024
- Apr 2nd, 2024 8:30 pm
Insider Buys Additional US$51k In Nuvectis Pharma Stock
- Mar 21st, 2024 10:08 am
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
- Mar 19th, 2024 12:00 pm
Nuvectis Pharma to Present at the 36th Annual Roth Conference
- Mar 15th, 2024 12:00 pm
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
- Mar 14th, 2024 1:00 pm
Nuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progress
- Mar 5th, 2024 1:31 pm
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
- Mar 5th, 2024 1:00 pm
Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownership
- Feb 19th, 2024 12:31 pm
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
- Feb 9th, 2024 1:32 pm
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
- Feb 9th, 2024 1:00 pm
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 1:00 pm
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
- Dec 18th, 2023 1:00 pm
Nuvectis Pharma Insiders Added US$3.75m Of Stock To Their Holdings
- Nov 25th, 2023 12:40 pm
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
- Nov 8th, 2023 1:00 pm
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
- Oct 24th, 2023 12:00 pm
We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully
- Oct 16th, 2023 5:55 pm
Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)
- Oct 16th, 2023 1:35 pm
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
- Sep 25th, 2023 11:30 pm
Scroll